相关实验视频

Updated: Sep 8, 2025

Enrichment of Astrocyte-Derived Extracellular Vesicles from Human Plasma

Enrichment of Astrocyte-Derived Extracellular Vesicles from Human Plasma

Published on: August 3, 2022

解读细胞外囊基治疗阿尔茨海默病的分子和信号通路

Rishika Dhapola¹, Sneha Kumari¹, Prajjwal Sharma¹

¹Advanced Pharmacology and Neuroscience Laboratory, Department of Pharmacology, School of Health Sciences, Central University of Punjab, Ghudda, Bathinda, 151401, Punjab, India.

Molecular neurobiology

|July 18, 2025

概括

细胞外囊泡 (EVs) 通过减少关键病理来治疗阿尔茨海默病 (AD) 是有前途的. 这些天然纳米颗粒为AD提供了一个生物相容且潜在的免疫性较低的治疗方法.

科学领域:

神经科学是一个神经科学.
生物技术是生物技术.
再生医学是一种再生医学.

背景情况:

由于人口老龄化,阿尔茨海默病 (AD) 构成了越来越大的挑战.
目前对阿尔茨海默病的治疗策略需要改进.
细胞外囊泡 (EVs) 正在成为阿尔茨海默病的新疗法选择.

研究的目的:

探索细胞外囊泡 (EV) 作为阿尔茨海默氏症 (AD) 治疗策略的潜力.
审查EVs改善AD病理和调节信号通路的机制.
评估基于EV的AD疗法的临床前和早期临床状态.

主要方法:

对针对AD的基于EV的疗法进行的临床前研究的审查.
分析EV特征,隔离方法和治疗优势.
检查EV介导对阿尔茨海默病的特征的影响,如粉样斑块和陶酸化.
研究EV对神经保护信号通路的影响.

主要成果:

EVs有效地改善了AD病理,包括粉样斑块形成,陶过,神经炎症,氧化应激和突触损失.
电脑调节关键信号通路 (例如NFκB,MAPK,Nrf2/Keap1) 以促进神经元的生长和生存.
临床前研究表明,来自各种来源 (MSC,NSC) 的EV可以减轻AD病理.
电动汽车具有诸如高生物可用性,生物相容性和低免疫性等优势.

结论:

电动干细胞代表了阿尔茨海默病的有希望的治疗途径,为干细胞治疗提供了一个潜在的非侵入性替代方案.
基于EV的疗法处于早期临床评估阶段,正在进行的试验评估安全性和有效性.
对于EV疗法的关键挑战包括大规模生产,剂量,生物分布和管理免疫反应.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.外基因组是外基因组的组成部分.细胞外囊泡中的细胞外囊泡.微小片是微小的片.分子路径的分子路径.治疗方法治疗方法

更多相关视频

Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections

Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections

Published on: November 8, 2024

Characterizing Extracellular Vesicles from Biological Fluids

Characterizing Extracellular Vesicles from Biological Fluids

Published on: February 28, 2025

相关概念视频

Overview of Exosomes

Overview of Exosomes

Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Intracellular Signaling Cascades

Intracellular Signaling Cascades

Once a ligand binds to a receptor, the signal is transmitted through the membrane and into the cytoplasm. The continuation of a signal in this manner is called signal transduction. Signal transduction only occurs with cell-surface receptors, which cannot interact with most components of the cell, such as DNA. Only internal receptors can interact directly with DNA in the nucleus to initiate protein synthesis. When a ligand binds to its receptor, conformational changes occur that affect the...